Understanding the economic and healthcare burden of metabolic dysfunction-associated steatohepatitis: a real-world claims data analysis from Germany
- 1 August 2026
- journal article
- Published by Becaris Publishing Limited in Journal of Comparative Effectiveness Research
- Vol. 15 (8)
Abstract
Aim: Metabolic dysfunction-associated steatohepatitis (MASH) is a progressive form of metabolic dysfunction-associated steatotic liver disease, linked to hepatic and extra-hepatic complications and substantial healthcare costs. Despite its clinical and economic impact, real-world evidence on disease progression and costs in Germany is limited. Materials & methods: We conducted a retrospective cohort study using statutory health insurance claims from the InGef database (2016–2023), covering 4.7% of the German population. Patients with MASH were identified using ICD-10-GM code K75.8, in absence of the more specific code in the German coding system. Baseline characteristics and comorbidities were assessed over 2 years prior to index diagnosis. Progression was defined by transitions through end-stage liver disease (ESLD) stages: compensated cirrhosis, decompensated cirrhosis, hepatocellular carcinoma and liver transplantation. Healthcare costs were analyzed descriptively and via regression models. Results: Among 4710 patients with MASH (prevalence: 0.15%), 39.4% had documented ESLD during follow-up (mean follow-up in days 1530). Disease progression to ESLD occurred in 26.0% of patients without baseline ESLD (n = 922/3490), whereas 4.0% of patients with baseline ESLD (n = 48/1188) progressed to a more severe ESLD stage during follow-up, with a mean time to first progression of approximately 25.3 months. Patients with ESLD incurred annual costs of €12,737 versus €4928 for those without ESLD. Progression to hepatocellular carcinoma and liver transplantation resulted in predicted costs of €12,948 and €75,719 per patient-year, respectively. Mortality was significantly higher among patients with ESLD (incidence rate ratio: 4.65; 95% CI: 3.76–5.79). Discussion: Over a quarter of identified patients with MASH already had advanced liver disease at baseline, suggesting potential underdiagnosis or late recognition in routine clinical practice. Early detection, proactive management and targeted therapies are essential to reduce progression and economic burden.Keywords
This publication has 26 references indexed in Scilit:
- Incidence of Cardiovascular Events and Extrahepatic Malignancies in Steatotic Liver Disease SubgroupsDigestive Diseases and Sciences, 2026
- Metabolic Dysfunction–Associated Steatotic Liver Disease in AdultsJAMA, 2026
- Incidence of Major Cardiovascular Events in Patients with Metabolic Dysfunction-Associated Steatotic Liver Disease in the General PopulationEuropean Journal of Heart Failure, 2025
- Projected Global Clinical, Humanistic, and Economic Impact of Metabolic Dysfunction-Associated Steatohepatitis (MASH): The Cost of Inaction Based on Data From Nine CountriesClinical Gastroenterology and Hepatology, 2025
- Understanding MASH: An Examination of Progression and Clinical Outcomes by Disease Severity in the TARGET-NASH DatabaseAdvances in Therapy, 2024
- Diabetes as a risk factor for MASH progressionDiabetes Research and Clinical Practice, 2024
- The Economic Burden of Non-Alcoholic Steatohepatitis: A Systematic ReviewPharmacoEconomics, 2022
- Global Epidemiology of Chronic Liver DiseaseClinical Liver Disease, 2021
- Nonalcoholic SteatohepatitisJAMA, 2020
- Fibrosis Progression in Nonalcoholic Fatty Liver vs Nonalcoholic Steatohepatitis: A Systematic Review and Meta-analysis of Paired-Biopsy StudiesClinical Gastroenterology and Hepatology, 2015